A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma

References

• Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842–858. doi:10.1056/NEJMra2027612.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu S, Farooq U et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808. doi:10.1182/blood-2017-03-769620.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Vose JM, Zinzani PL et al . An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol Off J Eur Soc Med Oncol. 2011;22(7):1622–1627. doi:10.1093/annonc/mdq626.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Lossos I, Tuscano JM et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(30):4952–4957. doi:10.1200/JCO.2007.15.3429.
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011;117(22):5058–5066. doi:10.1002/cncr.26135.
   PubMed Web of Science ®Google Scholar
• Vose JM, Habermann T, Czuczman MS et al. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. Br J Haematol. 2013;162(5):639–647. doi:10.1111/bjh.12449.
   PubMed Web of Science ®Google Scholar
• Mondello P, Steiner N, Willenbacher W et al. Lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: is it a valid treatment option? Oncologist. 2016;21(9):1107–1112. doi:10.1634/theoncologist.2016-0103.
   PubMed Web of Science ®Google Scholar
• Broccoli A, Casadei B, Chiappella A et al. Lenalidomide in pretreated patients with diffuse large B-cell lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. Oncologist. 2019;24(9):1246–1252. doi:10.1634/theoncologist.2018-0603.
   PubMed Web of Science ®Google Scholar
• Rodgers TD, Baran A, Reagan PM et al. Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma. Br J Haematol. 2020;188(4):e33–e36. doi:10.1111/bjh.16302.
   PubMed Web of Science ®Google Scholar
• Houot R, Cartron G, Bijou F et al. Obinutuzumab plus lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study. Leukemia. 2019;33(3):776–780. doi:10.1038/s41375-018-0282-y.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Pellegrini C, Gandolfi L et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk. 2011;11(6):462–466. doi:10.1016/j.clml.2011.02.001.
   PubMed Web of Science ®Google Scholar
• Wang M, Fowler N, Wagner-Bartak N et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013;27(9):1902–1909. doi:10.1038/leu.2013.95.
   PubMed Web of Science ®Google Scholar
• Ivanov V, Coso D, Chetaille B et al. Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2014;55(11):2508–2513. doi:10.3109/10428194.2014.889822.
   PubMed Web of Science ®Google Scholar
• Paillassa J, Vercellino L, Di Blasi R et al. Impact of bridging chemotherapy on clinical outcomes of CD19 CAR T therapy in relapse/refractory diffuse large B-cell lymphoma in real world experience. Blood. 2019;134(Suppl_1):2886–2886. doi:10.1182/blood-2019-129421.
   Google Scholar
• Dwivedy Nasta S, Hughes ME, Namoglu EC et al. A characterization of bridging therapies leading up to commercial CAR T-cell therapy. Blood. 2019;134(Suppl_1):4108–4108. doi:10.1182/blood-2019-131399.
   Google Scholar
• Otáhal P, Prukova D, Kral V et al. Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells. Oncoimmunology. 2016;5(4):e1115940. doi:10.1080/2162402X.2015.1115940.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Chevret S, Allain V et al. Lenalidomide enhance CAR T-cells response in patients with refractory/relapsed large B cell lymphoma experiencing progression after infusion. Blood. 2020;136(Suppl_1):16–17. doi:10.1182/blood-2020-136279.
   Google Scholar
• Ping N, Qu C, Li M et al. Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma. Ann Transl Med. 2022;10(6):298. doi:10.21037/atm-22-20.
   PubMed Web of Science ®Google Scholar
• Duell J, Maddocks KJ, Gonzalez-Barca E et al. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2021;106(9):2417–2426. doi:10.3324/haematol.2020.275958.
   PubMed Web of Science ®Google Scholar
• Jurczak W, Zinzani PL, Hess G et al. A phase IIa, open-label, multicenter study of single-agent tafasitamab (MOR208), an Fc-optimized anti-CD19 antibody, in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma: long-term follow-up, final analysis. Blood. 2019;134(Suppl_1):4078–4078. doi:10.1182/blood-2019-124297.
   Google Scholar
• Ward JP, Berrien-Elliot M, Gomez F et al. Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma. Blood. 2022;139(13):1999–2010. doi:10.1182/blood.2021011894.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Yasenchak CA, Ashraf K, et al. Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (ECHELON-3, trial in progress). Blood. 2021;138(Suppl_1):3564–3564. doi:10.1182/blood-2021-151583.
   Google Scholar